Latest Kaiser Health News Stories
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
More than 30 states have laws on the books to allow dying patients the right to try experimental treatments. But these treatments may not be covered by insurance, and ethicists worry vulnerable people could be exploited near the end of their lives. The laws may also duplicate a process the FDA already has in place.
Hundreds of drug brands are being made in giant contract facilities. When a plant shuts down, a widespread drain on supply can result.
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
Epinephrine, the active ingredient in EpiPens, expires after 18 months, and the auto-injector device can’t be refilled or reused. Health professionals are looking for work-arounds they say could save the health system millions.
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
Some terminal patients, typically high-dose opioid users, who choose to end their lives have taken many hours, even days, to die.
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
A study shows some emergency physicians wrote far more opioid prescriptions and Medicare patients who saw those doctors were more likely to still be taking the addictive painkillers months later.
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
Prescription pain pills are strong sellers in this southeastern Kentucky region that’s long struggled with high rates of joblessness and poor health.
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
Alzheimer’s researchers hold onto hope after another promising trial ends in disappointment.
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.
The device, known as Evzio, administers just enough naloxone to stabilize someone who has overdosed on drugs. But its manufacturer, Kaleo, may be positioning itself to find profits in a dire health care crisis.